Importance The COVID-19 pandemic saw one of the fastest developments of vaccines in an
effort to combat an out-of-control pandemic. The 2 most common COVID-19 vaccine …

Background: Though primarily a pulmonary disease, Coronavirus disease 2019 (COVID-19)
caused by the SARS-CoV-2 virus can generate devastating disease states that affect …

Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 …

Objective To assess the association between covid-19 vaccines and risk of
thrombocytopenia and thromboembolic events in England among adults. Design Self …

Objective To identify the rates of neurological events following administration of mRNA
(Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in the US Methods We used …

Objective We aimed to estimate the incidence of cerebral sinus and venous thrombosis
(CVT) within 1 month from first dose administration and the frequency of vaccine‐induced …

Background and purpose Cerebral venous sinus thrombosis (CVST) has been described
after vaccination against SARS‐CoV‐2. The clinical characteristics of 213 post‐vaccination …

Background A new syndrome of vaccine-induced immune thrombotic thrombocytopenia
(VITT) has emerged as a rare side-effect of vaccination against COVID-19. Cerebral venous …

Background: With 10 vaccines approved by the WHO and nearly 48% of people fully
vaccinated worldwide, we have observed several individual case studies of neurological …

Thrombosis that occurs in coronavirus disease 19 (COVID-19) is a serious complication and
a critical aspect of pathogenesis in the disease progression. Although thrombocytopenia is …